Aphios Granted United States Patent for Zindol

Published: Mar 04, 2013

WOBURN, Mass.--(BUSINESS WIRE)--Aphios Corporation today announced that it received notification of allowance for a United States Patent entitled “Use of Gingerols for Cancer Patients Suffering from Nausea and Emesis Induced by Chemotherapy.” Despite the widespread use of 5-HT3 receptor antagonist anti-emetics such as Palonosetron (Aloxi; Eisai), chemotherapy induced nausea continues to be reported by 70% of adult patients and 58% of children receiving highly emetogenic chemotherapy. Furthermore, these anti-emetics are associated with significant adverse effects such as sedation, extra-pyramidal side effects and hypotension as well as headache, diarrhea and constipation. A desirable attribute in any substitute or additional anti-emetic medication is the absence of clinically significant adverse effects.

Back to news